Siegfried Rejoins Dow Jones Best-in-Class Europe Index as Sole End-to-End CDMO

An announcement from Siegfried Holding AG ( (CH:SFZN) ) is now available.

Siegfried Holding AG, a Swiss-listed global CDMO for the pharmaceutical industry, operates 16 sites worldwide and focuses on manufacturing active pharmaceutical ingredients, intermediates and a broad range of drug products alongside development services. The group reported 2025 sales of CHF 1,327.8 million and employs more than 3,800 people, underlining its scale in outsourced pharmaceutical manufacturing.

The company has again been included in the Dow Jones Best-in-Class Europe Index, making it the only end-to-end CDMO represented in this established ESG benchmark and highlighting its strong sustainability performance. Management said the renewed inclusion reflects tangible progress in integrating ESG priorities into day-to-day operations across all sites, reinforcing Siegfried’s positioning as a sustainability leader in pharmaceutical manufacturing and potentially enhancing its appeal to customers and investors focused on responsible supply chains.

The most recent analyst rating on (CH:SFZN) stock is a Buy with a CHF109.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

More about Siegfried Holding AG

Siegfried Holding AG is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, with 16 sites across Europe, the U.S., Australia and China. The company manufactures active pharmaceutical ingredients and intermediates, as well as finished dosage forms such as tablets, capsules and sterile injectables, and also offers development services, generating CHF 1.33 billion in sales in 2025 with over 3,800 employees.

Average Trading Volume: 108,085

Technical Sentiment Signal: Hold

Current Market Cap: CHF3.6B

For detailed information about SFZN stock, go to TipRanks’ Stock Analysis page.